A citation-based method for searching scientific literature

Toby M Maher, Jeffrey J Swigris, Michael Kreuter, Marlies Wijsenbeek, Nicola Cassidy, Lucy Ireland, Judit Axmann, Steven D Nathan. Respiration 2018
Times Cited: 30







List of co-cited articles
165 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
66

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
63

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
53

Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Toby M Maher, Maria Molina-Molina, Anne-Marie Russell, Francesco Bonella, Stéphane Jouneau, Elena Ripamonti, Judit Axmann, Carlo Vancheri. BMC Pulm Med 2017
50
43

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
40

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
40

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
40

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
223
33

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R Collard, Inga Tschoepe, Susanne Stowasser, Arata Azuma. Am J Respir Crit Care Med 2016
157
30

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Helen E Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M A Hopkins, Yuben Moodley, Paul N Reynolds, Sally Chapman, E Haydn Walters, Christopher Zappala,[...]. Eur Respir J 2017
111
30

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.
Andreas Guenther, Ekaterina Krauss, Silke Tello, Jasmin Wagner, Bettina Paul, Stefan Kuhn, Olga Maurer, Sabine Heinemann, Ulrich Costabel, María Asunción Nieto Barbero,[...]. Respir Res 2018
124
30

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
Martin Kolb, Luca Richeldi, Jürgen Behr, Toby M Maher, Wenbo Tang, Susanne Stowasser, Christoph Hallmann, Roland M du Bois. Thorax 2017
121
26

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.
Michael Kreuter, Jeff Swigris, David Pittrow, Silke Geier, Jens Klotsche, Antje Prasse, Hubert Wirtz, Dirk Koschel, Stefan Andreas, Martin Claussen,[...]. Respir Res 2017
85
23

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.
Jürgen Behr, Michael Kreuter, Marius M Hoeper, Hubert Wirtz, Jens Klotsche, Dirk Koschel, Stefan Andreas, Martin Claussen, Christian Grohé, Henrike Wilkens,[...]. Eur Respir J 2015
133
23

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
663
23

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
112
20

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Jonathan A Galli, Aloknath Pandya, Michelle Vega-Olivo, Chandra Dass, Huaqing Zhao, Gerard J Criner. Respirology 2017
91
20

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
84
20

Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.
Harold R Collard, Luca Richeldi, Dong Soon Kim, Hiroyuki Taniguchi, Inga Tschoepe, Maurizio Luisetti, Jesse Roman, Gregory Tino, Rozsa Schlenker-Herceg, Christoph Hallmann,[...]. Eur Respir J 2017
73
20

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis.
Gareth Hughes, Hannah Toellner, Helen Morris, Colm Leonard, Nazia Chaudhuri. J Clin Med 2016
97
20

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
914
16

Optimizing quality of life in patients with idiopathic pulmonary fibrosis.
Mirjam J G van Manen, J J Miranda Geelhoed, Nelleke C Tak, Marlies S Wijsenbeek. Ther Adv Respir Dis 2017
44
16

A multidimensional index and staging system for idiopathic pulmonary fibrosis.
Brett Ley, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones,[...]. Ann Intern Med 2012
626
16

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Tamera Corte, Francesco Bonella, Bruno Crestani, Maurits G Demedts, Luca Richeldi, Carl Coeck, Katy Pelling, Manuel Quaresma, Joseph A Lasky. Respir Res 2015
76
16

Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients.
Gadi Schoenheit, Ian Becattelli, Alan H Cohen. Chron Respir Dis 2011
85
16

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.
Ida Pesonen, Lisa Carlson, Nicola Murgia, Riitta Kaarteenaho, Carl Magnus Sköld, Marjukka Myllärniemi, Giovanni Ferrara. Multidiscip Respir Med 2018
13
38

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.
Sophie V Fletcher, Mark G Jones, Elizabeth A Renzoni, Helen Parfrey, Rachel K Hoyles, Katherine Spinks, Maria Kokosi, Apollinaris Kwok, Chris Warburton, Vanessa Titmuss,[...]. ERJ Open Res 2018
13
38

The lived experience with idiopathic pulmonary fibrosis: a qualitative study.
Dorthe Overgaard, Gudrun Kaldan, Kristoffer Marsaa, Thyge Lynghøj Nielsen, Saher Burhan Shaker, Ingrid Egerod. Eur Respir J 2016
57
16



Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.
David A Lynch, Nicola Sverzellati, William D Travis, Kevin K Brown, Thomas V Colby, Jeffrey R Galvin, Jonathan G Goldin, David M Hansell, Yoshikazu Inoue, Takeshi Johkoh,[...]. Lancet Respir Med 2018
416
13

EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
Martina Doubková, Jan Švancara, Michal Svoboda, Martina Šterclová, Vladimír Bartoš, Martina Plačková, Ladislav Lacina, Monika Žurková, Ilona Binková, Radka Bittenglová,[...]. Clin Respir J 2018
30
13

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Michael Kreuter, Wim Wuyts, Elisabetta Renzoni, Dirk Koschel, Toby M Maher, Martin Kolb, Derek Weycker, Paolo Spagnolo, Klaus-Uwe Kirchgaessler, Felix J F Herth,[...]. Lancet Respir Med 2016
127
13

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Kenneth F Glasscock,[...]. Thorax 2016
102
13

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
588
13

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Kevin R Flaherty, Charlene D Fell, J Terrill Huggins, Hilario Nunes, Robert Sussman, Claudia Valenzuela, Ute Petzinger, John L Stauffer, Frank Gilberg, Monica Bengus,[...]. Eur Respir J 2018
48
13

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
110
13

Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.
Anne-Marie Russell, Huzaifa Adamali, Philip L Molyneaux, Pauline T Lukey, Richard P Marshall, Elisabetta A Renzoni, Athol U Wells, Toby M Maher. Am J Respir Crit Care Med 2016
85
13

Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Miya O Paterniti, Youwei Bi, Dinko Rekić, Yaning Wang, Banu A Karimi-Shah, Badrul A Chowdhury. Ann Am Thorac Soc 2017
71
13

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
461
13

European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers.
Francesco Bonella, Marlies Wijsenbeek, Maria Molina-Molina, Annette Duck, Rosalba Mele, Klaus Geissler, Wim Wuyts. Eur Respir J 2016
66
13

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
538
13

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events.
Elisabeth Bendstrup, Wim Wuyts, Tiago Alfaro, Nazia Chaudhuri, Robin Cornelissen, Michael Kreuter, Kirsten Melgaard Nielsen, Anna-Marie B Münster, Marjukka Myllärniemi, Claudia Ravaglia,[...]. Respiration 2019
23
17

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
522
13

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Eva Brunnemer, Julia Wälscher, Svenja Tenenbaum, Julia Hausmanns, Karen Schulze, Marianne Seiter, Claus Peter Heussel, Arne Warth, Felix J F Herth, Michael Kreuter. Respiration 2018
42
13

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wim A Wuyts, Caroline Dahlqvist, Hans Slabbynck, Marc Schlesser, Natacha Gusbin, Christophe Compere, Sofie Maddens, Klaus-Uwe Kirchgaessler, Karen Bartley, Benjamin Bondue. BMJ Open Respir Res 2018
24
16

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Monika Zurkova, Eva Kriegova, Vitezslav Kolek, Vladimira Lostakova, Martina Sterclova, Vladimir Bartos, Martina Doubkova, Ilona Binkova, Michal Svoboda, Jana Strenkova,[...]. Respir Res 2019
42
13

What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany.
Mirjam J G van Manen, Michael Kreuter, Bernt van den Blink, Ute Oltmanns, Karin Palmowski, Eva Brunnemer, Simone Hummler, Nelleke C Tak, Leon van den Toorn, Jelle Miedema,[...]. ERJ Open Res 2017
17
23

The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study.
Cathy Sampson, Ben Hope Gill, Nicholas Kim Harrison, Annmarie Nelson, Anthony Byrne. BMC Pulm Med 2015
54
13

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
223
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.